| Naslov: | Vismodegib in locally advanced basal cell carcinoma in Slovenia |
|---|
| Avtorji: | ID Mesti, Tanja (Avtor)
ID Sever, Maša (Avtor)
ID Ocvirk, Janja (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (448,27 KB)
MD5: 66E91885F3EF84346935C832F834BC41
 URL - Izvorni URL, za dostop obiščite https://www.karger.com/Article/Pdf/525612
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  OI - Onkološki inštitut Ljubljana
|
|---|
| Povzetek: | Background: Vismodegib is a first-in-class inhibitor of the hedgehog pathway for treatment of locally advanced basal cell carcinoma (laBCC) and metastatic BCC. Objectives: The purpose of this study is to report outcomes of patients with laBCC, with basal cell carcinoma nevus syndrome (Gorlin Goltz syndrome [G-G Syn]) treated with vismodegib in routine clinical practice in Slovenia in 8.3-year period. Methods: In this retrospective cohort study, we analyzed baseline characteristics, outcomes, and treatment-related adverse events from locally advanced BCC. The patients were divided into two cohorts: 39 laBCC or multiple BCC patients and 7 patients with G-G Syn who were treated with vismodegib from November 2012 till January 2021. Results: During 100-month period, 46 patients were diagnosed with laBCC (26), multiple BCC (13), and G-G Syn (7), all inappropriate for surgery or radiotherapy. Baseline characteristics: median age was 72.8 years in laBCC + multiple BCC cohort and 47.4 years in G-G Syn cohort. The objective response rate was 80% in laBCC + multiple BCC and 86% in G-G Syn cohort. Disease control rate (DCR) was 95% in laBCC + multiple BCC and 100% in G-G Syn cohort. Median duration of treatment was 9.9 months (range: 1.5-43.1) in laBCC and multiple BCC cohort and 19.5 months (range: 3.6-94.1) in G-G Syn cohort. Majority of treatment-emergent adverse events (TEAEs) in laBCC or multiple BCC cohort were grade 1 or 2 (96%), only 4% of AEs were grade 3. Majority of TEAEs in G-G Syn cohort were also grade 1 or 2 (87%), 13% of AEs were grade 3. No grade 4 or 5 vismodegib-related AEs were reported. Conclusion: Vismodegib has shown meaningful efficacy with DCR from 95% to 100% in patients with laBCC, multiple BCC, and G-G Syn in Slovenia. TEAEs were successfully alleviated with multidisciplinary approach and early supportive care. |
|---|
| Ključne besede: | basal cell carcinoma, early supportive care, Gorlin Goltz syndrome, multidisciplinary approach |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Datum objave: | 01.01.2022 |
|---|
| Založnik: | S. Karger |
|---|
| Leto izida: | 2022 |
|---|
| Št. strani: | str. 1-7 |
|---|
| Številčenje: | Vol. , no. |
|---|
| PID: | 20.500.12556/DiRROS-15459  |
|---|
| UDK: | 616.5 |
|---|
| ISSN pri članku: | 1018-8665 |
|---|
| DOI: | 10.1159/000525612 |
|---|
| COBISS.SI-ID: | 117583107 |
|---|
| Avtorske pravice: | by Authors |
|---|
| Datum objave v DiRROS: | 07.09.2022 |
|---|
| Število ogledov: | 768 |
|---|
| Število prenosov: | 422 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
